#2988
Epigenetic Treatment with Histone Deacetylase Inhibitor Enhances Uptake of [111In]In-DOTA-TATE by Increased SST2 Expression on Neuroendocrine Tumor Cells
Introduction:
The somatostatin-2 receptor (SST2) is a target for peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors (NETs). By using epigenetic drugs, which can regulate gene transcription, PRRT efficacy may be further improved due to enhanced SST2 expression.
Conference:
17th Annual ENETSConcerence (2020)
Presenting Author:
Klomp I
Authors:
Klomp I,
Dalm S,
van Koetsveld P,
Dogan-Oruç F,
de Jong M,
Keywords:
neuroendocrine tumors,
bon-1,
epigenetic,
histone,
histone deacetylase inhibitor,
HDACi,
upregulation,
reversibility,
somatostatin receptor-2,
somatostatin,
#2986
Characterization of 142 Human Pancreatic Neuroendocrine Tumors: ATRX and DAXX Correlation with Clinical-Pathological Data
Introduction:
Pancreatic neuroendocrine tumors (PNETs) are rare and heterogeneous neoplasms with a 10-year survival rate less than 30%. Up to 43% of them are driven by inactivating mutations in ATRX or DAXX. These are important players at chromatin remodeling, that when mutated prone cancer cells to initiate the alternative lengthening of telomeres (ALT). ALT phenotype correlates with in situ loss of expression of the proteins ATRX or DAXX and can be corroborated by telomere-FISH.
Conference:
17th Annual ENETSConcerence (2020)
Presenting Author:
Authors:
Gaspar T,
Pinheiro J,
Canberk S,
İnce �,
Tokat F,
Keywords:
pancreas,
pancreatic neuroendocrine tumors,
PNETs,
ATRX,
DAXX,
ALT,
mosaic,
#2958
The Blood-based Multigenomic NETest Accurately Identifies Neuroendocrine Transformed Prostate Cancer
Introduction:
Neuroendocrine differentiation and an aggressive phenotype is an important feature of castration-resistant prostate cancer (CRPC). Current biomarkers are unable to detect these advanced, treatment refractory variants.
Conference:
17th Annual ENETSConcerence (2020)
Presenting Author:
Modlin I
Authors:
Modlin I,
Kidd M,
Rahbar K,
Malczewska A,
Rajwa P,
Keywords:
Biomarker,
NETest,
PSA,
prostate cancer,
neuroendocrine phenotype,
castration-resistance,
neuroendocrine,
#2934
Vasostatin-1 Predicts Recurrence in Patients Submitted to Surgery for Nonfunctioning Pancreatic Neuroendocrine Tumors (NF-PanNET)
Introduction:
An association between preoperative Vasostatin-1 (VS-1) plasma level and pathological features of aggressiveness was previously reported in patients with surgically resected nonfunctioning (NF) PanNET.
Conference:
17th Annual ENETSConcerence (2020)
Presenting Author:
Andreasi V
Authors:
Andreasi V,
Partelli S,
Manzoni M,
Muffatti F,
Colombo B,
Keywords:
pancreatic neuroendocrine tumors,
biomarkers,
chromogranin A,
vasostatin 1,
recurrence,
